Fig. 9From: Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational seriesThe metastatic para-aortic lymph node pointed with arrow. Notes: a recurrence before chemotherapy. b partial response after chemotherapy/pretreatment of OlaparibBack to article page